Lupus Nephritis 2024 Guidelines
The ACR has published evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis (LN). These are the same guidelines presented at ACR Convergence 2024.
Lupus in an empty house
The full house immunofluorescence pattern is the classic histopathologic finding of lupus and lupus nephritis. Glomerular deposits staining for IgG, IgA, IgM, C3 and C1q can help confirm a suspected diagnosis of systemic lupus erythematosus (SLE).
Deep remission in SLE – what is it, and can we achieve it?
Recent reports on small numbers of lupus patients treated with CAR-T cells directed against CD19+ B lymphocytes have generated considerable excitement, not so much because the initial response to this therapy was favorable, but because after follow-up durations of two years or longer th
Lessons Learned from a Lupus Registry: Two sides of one coin?
It's Dr. Janet Pope reporting at RheumNow on our special lupus edition. I'd like to talk about lessons learned from a Canadian lupus registry. Is it two sides of one coin?
What do I mean by that?
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy
What are the major differences between these two guidelines?
Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
SLE Perspectives: Past, Present, Future
From fellowship through current times to looking ahead to the future, here are my lupus perspectives.
PAST:
Emulation trials in SLE: Real or Fake?
Recently a landmark paper was published in A&R studying the results of an emulation trial (1). My colleagues and I were able to write an editorial on this paper and describe emulation trials (2).
More Women with Autoimmune Diseases Die from Cardiovascular Disease
- In a study focused on individuals with the immune-mediated inflammatory diseases rheumatoid arthritis, lupus or systemic sclerosis, the overall cardiovascular disease-related death decreased for all participants between 1999 and 2020.
From DNA to PGA
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in systemic lupus erythematosus (SLE) since 1978. In this pursuit, I have followed the advice of my first division chief, Dr.
Prophylaxis Against PJP in SLE: I'll Pass
Hi everybody. It’s Mike Putman. I'm an assistant professor of medicine at the Medical College of Wisconsin in Milwaukee, Wisconsin, and I am here talking to you with RheumNow about my favorite, least favorite topic, which is PJP prophylaxis.
Stable SLE - Should you Withdraw Immunosuppressant or Glucocorticoids?
An open-label, single-centre, randomized controlled trial tested whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in systemic lupus erythematosus (SLE) patients and found that IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term
Glucocorticoids in SLE: how to start, how to follow, how to stop
More than 70 years after their first use in rheumatology by Philip Hench, glucocorticoids (GCs) continue to be one of the main weapons to fight systemic lupus erythematosus (SLE).
Keys to Mastery (5.2.2025)
Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.
Secondary Benefits to SGLT2 Inhibitor Use in SLE
An emulation trial of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in systemic lupus erythematosus (SLE) patients yielded a significantly reduced risk of several cardiorenal complications among patients with SLE and type 2 diabetes (T2D).
Contraception in SLE
Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy.
Genetic Analysis of Asymptomatic Antinuclear Antibody Positive Patients
A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk.
Video
Podcasts
Rx Update - Lupus Nephritis
Lupus Unlocked- Pregnancy and SLE
Lupus QD Clinics - lessons from the Clinic - Week 3